Accumulation of Fra-1 in Ras-transformed Cells Depends on Both Transcriptional Autoregulation and MEK-dependent Posttranslational Stabilization

Overview

Journal Mol Cell Biol

Specialty Cell Biology

Date 2003 May 30

PMID 12773579

Citations 46

Authors

Laura Casalino

Dario De Cesare

Pasquale Verde

Affiliations

Soon will be listed here.

Abstract

The AP-1 transcription factor plays an essential role in cell proliferation and tumorigenesis. It was previously shown that the fra-1 gene product is upregulated by various oncogenes and is involved in the in vitro and in vivo transformation of thyroid cells. Here we show that the ras oncogene-dependent accumulation of Fra-1 is mediated by a positive feedback mechanism which requires both transcriptional autoregulation and posttranslational stabilization of the protein. The oncogene-dependent transcriptional activation involves the cooperation between both Raf-dependent and Raf-independent pathways and is mediated by an AP-1 site within the fra-1 first intron, which becomes stably occupied by a transcriptionally active Fra-1-containing complex in ras-transformed cells. The posttranslational stabilization results in a drastic increase in the Fra-1 half-life in ras-transformed cells and is totally dependent on the activity of the MEK/ERK phosphorylation pathway. The analysis of the Fra-1 transactivation potential shows that the protein is able to stimulate a heterologous promoter in a ras-dependent manner, but the transactivating activity requires the recruitment of a heterodimeric partner. These data show that the alteration of multiple regulatory mechanisms is required for the constitutive activation of Fra-1 as a nuclear target of ras transformation.

Citing Articles

Cooperation between the Hippo and MAPK pathway activation drives acquired resistance to TEAD inhibition.

Paul S, Hagenbeek T, Tremblay J, Kameswaran V, Ong C, Liu C Nat Commun. 2025; 16(1):1743.

PMID: 39966375 PMC: 11836325. DOI: 10.1038/s41467-025-56634-y.

Saikosaponin A Recovers Impaired Filaggrin Levels in Inflamed Skin by Downregulating the Expression of FRA1 and c-Jun.

Ahn S, Yeo H, Jung E, Kim T, Han J, Han Lee Y Molecules. 2024; 29(17).

PMID: 39274912 PMC: 11396542. DOI: 10.3390/molecules29174064.

FRA1 controls acinar cell plasticity during murine Kras-induced pancreatic acinar to ductal metaplasia.

Li A, Sugiura K, Nishiwaki N, Suzuki K, Sadeghian D, Zhao J Dev Cell. 2024; 59(22):3025-3042.e7.

PMID: 39178842 PMC: 11576252. DOI: 10.1016/j.devcel.2024.07.021.

FOSL1's Oncogene Roles in Glioma/Glioma Stem Cells and Tumorigenesis: A Comprehensive Review.

Khedri A, Guo S, Ramar V, Hudson B, Liu M Int J Mol Sci. 2024; 25(10.

PMID: 38791400 PMC: 11121637. DOI: 10.3390/ijms25105362.

TRPM7 transactivates the FOSL1 gene through STAT3 and enhances glioma stemness.

Guo S, Ramar V, Guo A, Saafir T, Akpobiyeri H, Hudson B Cell Mol Life Sci. 2023; 80(9):270.

PMID: 37642779 PMC: 10465393. DOI: 10.1007/s00018-023-04921-6.

References

Casamassimi A, Miano M, Porcellini A, De Vita G, De Nigris F, Zannini M . p53 genes mutated in the DNA binding site or at a specific COOH-terminal site exert divergent effects on thyroid cell growth and differentiation. Cancer Res. 1998; 58(13):2888-94. View

Philips A, Teyssier C, Galtier F, Rey J, ROCHEFORT H, Chalbos D . FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells. Mol Endocrinol. 1998; 12(7):973-85. DOI: 10.1210/mend.12.7.0133. View

Zuber J, Tchernitsa O, Hinzmann B, Schmitz A, Grips M, Hellriegel M . A genome-wide survey of RAS transformation targets. Nat Genet. 2000; 24(2):144-52. DOI: 10.1038/72799. View

Missero C, Pirro M, Di Lauro R . Multiple ras downstream pathways mediate functional repression of the homeobox gene product TTF-1. Mol Cell Biol. 2000; 20(8):2783-93. PMC: 85494. DOI: 10.1128/MCB.20.8.2783-2793.2000. View

Bakiri L, lAllemand D, Bossy-Wetzel E, Yaniv M . Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J. 2000; 19(9):2056-68. PMC: 305681. DOI: 10.1093/emboj/19.9.2056. View

Adamkiewicz J, Wimmel A, Schuermann M . Transition from SCLC to NSCLC phenotype is accompanied by an increased TRE-binding activity and recruitment of specific AP-1 proteins. Oncogene. 1998; 16(23):3057-68. DOI: 10.1038/sj.onc.1201845. View

Suarez H . Genetic alterations in human epithelial thyroid tumours. Clin Endocrinol (Oxf). 1998; 48(5):531-46. DOI: 10.1046/j.1365-2265.1998.00443.x. View

Battista S, De Nigris F, Fedele M, Chiappetta G, Scala S, Vallone D . Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo. Oncogene. 1998; 17(3):377-85. DOI: 10.1038/sj.onc.1201953. View

Brown J, Nigh E, Lee R, Ye H, Thompson M, Saudou F . Fos family members induce cell cycle entry by activating cyclin D1. Mol Cell Biol. 1998; 18(9):5609-19. PMC: 109145. DOI: 10.1128/MCB.18.9.5609. View

10.

Campbell S, Khosravi-Far R, Rossman K, Clark G, Der C . Increasing complexity of Ras signaling. Oncogene. 1998; 17(11 Reviews):1395-413. DOI: 10.1038/sj.onc.1202174. View

11.

Cobellis G, Missero C, Di Lauro R . Concomitant activation of MEK-1 and Rac-1 increases the proliferative potential of thyroid epithelial cells, without affecting their differentiation. Oncogene. 1998; 17(16):2047-57. DOI: 10.1038/sj.onc.1202130. View

12.

Kustikova O, Kramerov D, Grigorian M, Berezin V, Bock E, Lukanidin E . Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol Cell Biol. 1998; 18(12):7095-105. PMC: 109291. DOI: 10.1128/MCB.18.12.7095. View

13.

Treinies I, PATERSON H, Hooper S, Wilson R, Marshall C . Activated MEK stimulates expression of AP-1 components independently of phosphatidylinositol 3-kinase (PI3-kinase) but requires a PI3-kinase signal To stimulate DNA synthesis. Mol Cell Biol. 1998; 19(1):321-9. PMC: 83890. DOI: 10.1128/MCB.19.1.321. View

14.

Cook S, Aziz N, McMahon M . The repertoire of fos and jun proteins expressed during the G1 phase of the cell cycle is determined by the duration of mitogen-activated protein kinase activation. Mol Cell Biol. 1998; 19(1):330-41. PMC: 83891. DOI: 10.1128/MCB.19.1.330. View

15.

Wisdom R, Johnson R, Moore C . c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J. 1999; 18(1):188-97. PMC: 1171114. DOI: 10.1093/emboj/18.1.188. View

16.

Schreiber M, Kolbus A, Piu F, Szabowski A, Tian J, Karin M . Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev. 1999; 13(5):607-19. PMC: 316508. DOI: 10.1101/gad.13.5.607. View

17.

Murakami M, Ui M, Iba H . Fra-2-positive autoregulatory loop triggered by mitogen-activated protein kinase (MAPK) and Fra-2 phosphorylation sites by MAPK. Cell Growth Differ. 1999; 10(5):333-42. View

18.

Gille H, Downward J . Multiple ras effector pathways contribute to G(1) cell cycle progression. J Biol Chem. 1999; 274(31):22033-40. DOI: 10.1074/jbc.274.31.22033. View

19.

Young M, Li J, Rincon M, Flavell R, Sathyanarayana B, Hunziker R . Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci U S A. 1999; 96(17):9827-32. PMC: 22295. DOI: 10.1073/pnas.96.17.9827. View

20.

Passegue E, Jochum W, Schorpp-Kistner M, Wagner E . Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage. Cell. 2001; 104(1):21-32. DOI: 10.1016/s0092-8674(01)00188-x. View